Myths In The Pricing Of New Drugs Forbes The UK watchdog, NICE (National Institute for health and Clinical Excellence) rejected Bayer's liver cancer drug, sorafenib (sold as Nexavar), because it felt that the price (3,500 pounds per patient per month) was too high to justify use by the ... |
